Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments
暂无分享,去创建一个
[1] K. Khunti,et al. Effect of Conventional Lifestyle Interventions on Type 2 Diabetes Incidence by Glucose-Defined Prediabetes Phenotype: An Individual-Participant Data Meta-analysis of Randomized Controlled Trials. , 2023, Diabetes care.
[2] S. Jaffar,et al. Metformin for the prevention of diabetes among people with HIV and either impaired fasting glucose or impaired glucose tolerance (prediabetes) in Tanzania: a Phase II randomised placebo-controlled trial , 2023, Diabetologia.
[3] H. Katsuyama,et al. Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study , 2023, Biomedicines.
[4] H. Katsuyama,et al. Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk , 2022, International journal of molecular sciences.
[5] A. Marais,et al. Effect of evolocumab on fasting and post fat load lipids and lipoproteins in familial dysbetalipoproteinemia. , 2022, Journal of clinical lipidology.
[6] H. Katsuyama,et al. A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes , 2022, Cardiology research.
[7] M. Castro Cabezas,et al. Effects of dapagliflozin on postprandial lipid metabolism in type 2 diabetes mellitus. , 2022, European journal of endocrinology.
[8] H. Katsuyama,et al. Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study , 2022, Biomedicines.
[9] Y. Mu,et al. Network Meta-Analysis of the Therapeutic Effects of Hypoglycemic Drugs and Intensive Lifestyle Modification on Impaired Glucose Tolerance. , 2021, Clinical therapeutics.
[10] N. Chandra. A comprehensive account of insulin and LDL receptor activity over the years: A highlight on their signaling and functional role , 2021, Journal of biochemical and molecular toxicology.
[11] H. Katsuyama,et al. Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors , 2021, International journal of molecular sciences.
[12] N. Lundbom,et al. Effects of liraglutide on the metabolism of triglyceride‐rich lipoproteins in type 2 diabetes , 2021, Diabetes, obesity & metabolism.
[13] B. Richter,et al. Pioglitazone for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus. , 2020, The Cochrane database of systematic reviews.
[14] Daniel E Forman,et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.
[15] E. Nozaki,et al. Impact of decreased insulin resistance by ezetimibe on postprandial lipid profiles and endothelial functions in obese, non-diabetic-metabolic syndrome patients with coronary artery disease , 2018, Heart and Vessels.
[16] S. Yamashita,et al. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. , 2018, Journal of clinical lipidology.
[17] G. Chiabrando,et al. The Role of Low-Density Lipoprotein Receptor-Related Protein 1 in Lipid Metabolism, Glucose Homeostasis and Inflammation , 2018, International journal of molecular sciences.
[18] P. Gill,et al. Risk of chronic kidney disease in young adults with impaired glucose tolerance/impaired fasting glucose: a retrospective cohort study using electronic primary care records , 2018, BMC Nephrology.
[19] S. Hattori. Empagliflozin decreases remnant‐like particle cholesterol in type 2 diabetes patients with insulin resistance , 2017, Journal of diabetes investigation.
[20] T. Lüscher,et al. Impact of Glycemic Variability on Chromatin Remodeling, Oxidative Stress, and Endothelial Dysfunction in Patients With Type 2 Diabetes and With Target HbA1c Levels , 2017, Diabetes.
[21] H. Katsuyama,et al. Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data , 2017, Journal of clinical medicine research.
[22] Y. Izumiya,et al. Effects of the Mean Amplitude of Glycemic Excursions and Vascular Endothelial Dysfunction on Cardiovascular Events in Nondiabetic Patients With Coronary Artery Disease , 2017, Journal of the American Heart Association.
[23] M. Kakuda,et al. The Effect of Tofogliflozin Treatment on Postprandial Glucose and Lipid Metabolism in Japanese Men With Type 2 Diabetes: A Pilot Study , 2017, Journal of clinical medicine research.
[24] M. Soares,et al. Plasma triglyceride and high density lipoprotein cholesterol are poor surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with the metabolic syndrome , 2016, Lipids in Health and Disease.
[25] N. Hashimoto,et al. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective ran , 2016, Cardiovascular Diabetology.
[26] F. Kronenberg,et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Med , 2016, Clinical chemistry.
[27] Hiroshi Ito,et al. Postprandial hyperlipidemia as a potential residual risk factor. , 2016, Journal of cardiology.
[28] R. Hegele,et al. Combined hyperlipidemia: familial but not (usually) monogenic , 2016, Current opinion in lipidology.
[29] N. Tada,et al. Understanding of Diabetic Dyslipidemia by Using the Anion-Exchange High Performance Liquid Chromatography Data , 2016, Journal of clinical medicine research.
[30] Olga V. Demler,et al. Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State. , 2015, Clinical chemistry.
[31] Akhilesh Rao,et al. Lipid abnormalities in kidney disease and management strategies. , 2015, World journal of nephrology.
[32] A. Liem,et al. Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls. , 2015, Metabolism: clinical and experimental.
[33] A. D'Angelo,et al. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. , 2014, Metabolism: clinical and experimental.
[34] H. Morita,et al. Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: a randomized crossover study , 2014, Cardiovascular Diabetology.
[35] A. Pietraszek,et al. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial , 2013, Diabetes, obesity & metabolism.
[36] N. Tada,et al. Relevance of intermediate-density lipoprotein cholesterol to Framingham risk score of coronary heart disease in middle-aged men with increased non-HDL cholesterol. , 2013, International journal of cardiology.
[37] Mary E. Haas,et al. The regulation of ApoB metabolism by insulin , 2013, Trends in Endocrinology & Metabolism.
[38] H. Morita,et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non- diabetic subjects: a preliminary report , 2013, Cardiovascular Diabetology.
[39] K. Nakajima,et al. The characteristics of remnant lipoproteins in the fasting and postprandial plasma. , 2012, Clinica chimica acta; international journal of clinical chemistry.
[40] N. Tada,et al. Estimation of lipoprotein profile in patients with type II diabetes and its relevance to remnant lipoprotein cholesterol levels. , 2012, Atherosclerosis.
[41] E. Fisher. The degradation of apolipoprotein B100: multiple opportunities to regulate VLDL triglyceride production by different proteolytic pathways. , 2012, Biochimica et biophysica acta.
[42] F. Kantarcı,et al. Glucose intolerance: is it a risk factor for cardiovascular disease in children with chronic kidney disease? , 2012, Pediatric Nephrology.
[43] H. Hamasaki,et al. Effects of Liraglutide, a Human Glucagon-Like Peptide-1 Analog, on Glucose/Lipid Metabolism, and Adipocytokines in Patients With Type 2 Diabetes , 2011 .
[44] H. Mabuchi,et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. , 2011, Clinica chimica acta; international journal of clinical chemistry.
[45] K. Cianflone,et al. The therapeutic role of very low-density lipoprotein receptor gene in hyperlipidemia in type 2 diabetic rats. , 2011, Human gene therapy.
[46] M. Taskinen,et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. , 2010, Atherosclerosis.
[47] S. Hidaka,et al. Postprandial hyperglycemia and hyperinsulinemia associated with renal arterio-arteriolosclerosis in chronic kidney disease , 2010, Hypertension Research.
[48] K. Shimamoto,et al. Increased serum apolipoprotein B48 concentration in patients with metabolic syndrome. , 2009, Journal of atherosclerosis and thrombosis.
[49] C. Lamendola,et al. Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin‐resistant smokers , 2009, Diabetes, obesity & metabolism.
[50] S. Yamashita,et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia , 2009, European journal of clinical investigation.
[51] P. Talmud,et al. Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. , 2009, Atherosclerosis.
[52] T. Miida,et al. Measurement of cholesterol concentrations of major serum lipoprotein classes in haemodialysis patients by anion-exchange chromatography , 2008, Annals of clinical biochemistry.
[53] J. O’Keefe,et al. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. , 2008, Journal of the American College of Cardiology.
[54] N. Tada,et al. Effects of Diacylglycerol on Glucose, Lipid Metabolism, and Plasma Serotonin Levels in Lean Japanese , 2008, Obesity.
[55] S. Yamashita,et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. , 2007, Clinical chemistry.
[56] M. Taskinen,et al. The Increase of Apolipoprotein A-V During Postprandial Lipemia Parallels the Response of Triglyceride-Rich Lipoproteins in Type 2 Diabetes , 2007, Diabetes Care.
[57] K. Ikewaki,et al. Increased remnant lipoprotein in patients with coronary artery disease--evaluation utilizing a newly developed remnant assay, remnant lipoproteins cholesterol homogenous assay (RemL-C). , 2007, Journal of atherosclerosis and thrombosis.
[58] A. Stalenhoef,et al. High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia. , 2007, The Journal of clinical endocrinology and metabolism.
[59] G. Tomkin,et al. Genes that affect cholesterol synthesis, cholesterol absorption, and chylomicron assembly: the relationship between the liver and intestine in control and streptozotosin diabetic rats. , 2007, Metabolism: clinical and experimental.
[60] K. Adeli,et al. Lipid and lipoprotein dysregulation in insulin resistant states. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[61] G. Tomkin,et al. Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann–Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein , 2006, Diabetologia.
[62] N. Tajima,et al. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in japanese patients with type 2 diabetes , 2006, Endocrine.
[63] B. Patterson,et al. Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity. , 2004, The Journal of clinical endocrinology and metabolism.
[64] M. Banerji,et al. Postprandial Hyperlipidemia after a Fat Loading Test in Minority Adolescents with Type 2 Diabetes Mellitus and Obesity , 2004, Journal of pediatric endocrinology & metabolism : JPEM.
[65] J. Brunzell,et al. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. , 2004, The Journal of clinical endocrinology and metabolism.
[66] J. Holst,et al. Incretins, insulin secretion and Type 2 diabetes mellitus , 2004, Diabetologia.
[67] J. Shaw,et al. Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.
[68] K. Hermansen,et al. Incremental area under response curve more accurately describes the triglyceride response to an oral fat load in both healthy and type 2 diabetic subjects. , 2003, Metabolism: clinical and experimental.
[69] S. Deeb,et al. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. , 2003, Journal of lipid research.
[70] L. Eberly,et al. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. , 2003, Archives of internal medicine.
[71] C. V. van Duijn,et al. Expression of Type III Hyperlipoproteinemia in Apolipoprotein E2 (Arg158→Cys) Homozygotes Is Associated With Hyperinsulinemia , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[72] G. Reaven,et al. Relationship between plasma insulin concentration and plasma remnant lipoprotein response to an oral fat load in patients with type 2 diabetes. , 2001, Journal of the American College of Cardiology.
[73] J. Hokanson,et al. The contribution of intraabdominal fat to gender differences in hepatic lipase activity and low/high density lipoprotein heterogeneity. , 2001, The Journal of clinical endocrinology and metabolism.
[74] M. Emoto,et al. Atherogenic lipoprotein changes in diabetic nephropathy. , 2001, Atherosclerosis.
[75] H. Iso,et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. , 2001, American journal of epidemiology.
[76] R. Havel. Remnant lipoproteins as therapeutic targets , 2000, Current opinion in lipidology.
[77] D. Erkelens,et al. In vivo evidence of defective postprandial and postabsorptive free fatty acid metabolism in familial combined hyperlipidemia. , 2000, Journal of lipid research.
[78] D. Rudy,et al. Mechanisms of Hepatic Very Low Density Lipoprotein Overproduction in Insulin Resistance , 2000, The Journal of Biological Chemistry.
[79] R. Cantor,et al. Contribution of the hepatic lipase gene to the atherogenic lipoprotein phenotype in familial combined hyperlipidemia. , 2000, Journal of lipid research.
[80] R. Mahley,et al. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. , 1999, Journal of lipid research.
[81] M. Tremblay,et al. Characterization of remnant-like particles isolated by immunoaffinity gel from the plasma of type III and type IV hyperlipoproteinemic patients. , 1999, Journal of lipid research.
[82] M. Weintraub,et al. Effects of fibric acid derivatives and metformin on postprandial lipemia. , 1998, Atherosclerosis.
[83] M. Noritake,et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. , 1998, Diabetes research and clinical practice.
[84] Viikari,et al. Glucose intolerance in familial combined hyperlipidaemia , 1998 .
[85] J. Real,et al. Influence of obesity on plasma lipoproteins, glycaemia and insulinaemia in patients with familial combined hyperlipidaemia , 1997, International Journal of Obesity.
[86] M. Leutenegger,et al. Postprandial cholesteryl ester transfer and high density lipoprotein composition in normotriglyceridemic non-insulin-dependent diabetic patients. , 1996, Atherosclerosis.
[87] F. Kraemer,et al. Regulation of hormone-sensitive lipase in streptozotocin-induced diabetic rats. , 1995, Metabolism: clinical and experimental.
[88] Christine M. Williams,et al. Polyunsaturated fatty acids of the n-6 and n-3 series: effects on postprandial lipid and apolipoprotein levels in healthy men. , 1994, European journal of clinical nutrition.
[89] D. Erkelens,et al. Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides* , 1994, European journal of clinical investigation.
[90] A. Hardman,et al. The effect of a single bout of brisk walking on postprandial lipemia in normolipidemic young adults. , 1994, Metabolism: clinical and experimental.
[91] T. Lehtimäki,et al. Postprandial plasma lipoprotein changes in relation to apolipoprotein E phenotypes and low density lipoprotein size in men with and without coronary artery disease. , 1994, Atherosclerosis.
[92] R. Havel. Postprandial hyperlipidemia and remnant lipoproteins. , 1994, Current opinion in lipidology.
[93] B. Föger,et al. Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia , 1994, The clinical investigator.
[94] J. Taylor,et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. , 1994, The Journal of biological chemistry.
[95] K. Nakajima,et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. , 1993, Clinica chimica acta; international journal of clinical chemistry.
[96] T. D. de Bruin,et al. Impaired chylomicron remnant clearance in familial combined hyperlipidemia. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.
[97] T. D. de Bruin,et al. Simvastatin improves chylomicron remnant removal in familial combined hyperlipidemia without changing chylomicron conversion. , 1993, Metabolism: clinical and experimental.
[98] J. K. Dunn,et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.
[99] R. DeFronzo. Pathogenesis of Type 2 (non-insulin dependent) diabetes mellitus: a balanced overview , 1992, Diabetologia.
[100] R. Havel,et al. Properties of an apolipoprotein E-enriched fraction of triglyceride-rich lipoproteins isolated from human blood plasma with a monoclonal antibody to apolipoprotein B-100. , 1992, Journal of lipid research.
[101] D. Johnston,et al. The Role of Insulin Insensitivity and Hepatic Lipase in the Dyslipidaemia of Type 2 Diabetes , 1991, Diabetic medicine : a journal of the British Diabetic Association.
[102] P. Nestel,et al. Increased lipoprotein-remnant formation in chronic renal failure. , 1982, The New England journal of medicine.
[103] E. Levy,et al. Impaired intestinal fat absorption in chronic renal failure. , 1982, Nephron.
[104] R. Havel,et al. Metabolism of apolipoprotein A-I of chylomicrons in rats and humans. , 1981, Canadian journal of biochemistry.
[105] D. B. Zilversmit. Atherogenesis: a postprandial phenomenon. , 1979, Circulation.
[106] M. Taskinen,et al. Relation of plasma high-density lipoprotein cholesterol to lipoprotein-lipase activity in adipose tissue and skeletal muscle of man. , 1978, Atherosclerosis.
[107] J. Huttunen,et al. Postheparin Plasma Lipoprotein Lipase and Hepatic Lipase in Diabetes Mellitus: Relationship to Plasma Triglyceride Metabolism , 1977, Diabetes.
[108] A. Motulsky,et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. , 1973, The Journal of clinical investigation.
[109] J. Zhao,et al. Relationship between blood glucose fluctuation and macrovascular endothelial dysfunction in type 2 diabetic patients with coronary heart disease. , 2014, European review for medical and pharmacological sciences.
[110] T. Abe,et al. Chronic kidney disease, dyslipidemia, and atherosclerosis. , 2012, Journal of atherosclerosis and thrombosis.
[111] S. Yamashita,et al. Fasting serum apolipoprotein B-48 can be a marker of postprandial hyperlipidemia. , 2011, Journal of atherosclerosis and thrombosis.
[112] M. Fernández,et al. Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C) , 2008, Lipids in Health and Disease.
[113] I. Miyamori,et al. The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor. , 2004, Journal of atherosclerosis and thrombosis.
[114] J. Ansquer,et al. Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control. , 2003, Atherosclerosis.
[115] N. H. Nguyen,et al. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. , 2000, Journal of cardiovascular pharmacology.
[116] T. Taniguchi,et al. Elevated remnant-like lipoprotein particles in impaired glucose tolerance and type 2 diabetic patients. , 1999, Diabetes care.
[117] G. Reaven,et al. Effect of acute variations in dietary fat and carbohydrate intake on retinyl ester content of intestinally derived lipoproteins. , 1992, The Journal of clinical endocrinology and metabolism.